Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy

Sina Haeri, Marla Shauer, Monica Dale, Jennie Leslie, Arthur M. Baker, Stephanie Saddlemire, Kim Boggess

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Objective: Our aim was to examine perinatal outcomes in women who are infected with human immunodeficiency virus (HIV) and who receive highly active antiretroviral therapy compared with the general population. Study Design: In this retrospective cohort study, we compared 151 HIV-positive and 302 HIV-negative women. We defined highly active antiretroviral therapy as concomitant use of at least 3 antiretroviral drugs. We calculated frequencies and odds ratios for adverse pregnancy outcomes. Results: Compared with control subjects, smoking (odds ratio, 4.62; 95% confidence interval [CI], 2.58-8.27), drug abuse (odds ratio, 5.48; 95% CI, 2.21-13.59), and spontaneous preterm birth (adjusted odds ratio, 2.27; 95% CI, 1.22-4.25) were more common among HIV-positive women. HIV-positive women were more likely to deliver a small-for-gestational-age infant, but this was due to higher tobacco and cocaine use. Neonatal outcomes were otherwise similar. Conclusion: HIV-positive women are at increased risk for preterm birth and lower birthweight infants; therefore, antenatal surveillance should include fetal growth assessment. Highly active antiretroviral therapy use does not increase maternal complications.

Original languageEnglish (US)
Pages (from-to)315.e1-315.e5
JournalAmerican journal of obstetrics and gynecology
Volume201
Issue number3
DOIs
StatePublished - Sep 2009

Keywords

  • highly active antiretroviral therapy
  • human immunodeficiency virus
  • low birthweight
  • pregnancy
  • preterm birth

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy'. Together they form a unique fingerprint.

  • Cite this